Pricing Log in Create free account
Friday 6 November 2026 Export PBH’s income statement to Excel — free account

Prestige Consumer Healthcare Inc.

PBH Healthcare Drug Manufacturers Specialty & Generic

Prestige Consumer Healthcare Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 billion, down 4.31% from fiscal 2025.

Revenue
+22.7%
EPS
−38.4%
Free cash flow
−38.2%
Total debt
+100.9%

Quarter to September 2026, against a year earlier

42.56 1.76 −3.97%
Market cap
$2.1B
P/E
13.7×
Fwd P/E
11.7×
Dividend yield
—
F-score
5/9
Altman Z
2.48
Beneish M
−2.53
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Prestige Consumer Healthcare Inc. (PBH) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Prestige Consumer Healthcare Inc. (PBH) trades at a EV/Sales of 3.5×. Over the past ten years it has ranged from 2.9× (June 2026) to 5.9× (April 2017); the current reading is higher than 11% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.9× and in line with the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2026 3.5× (22.99%)
FY2025 4.6× 10.41%
FY2024 4.1× 5.48%
FY2023 3.9× 3.38%
FY2022 3.8× (2.61%)
FY2021 3.9× 6.97%
FY2020 3.6× 7.45%
FY2019 3.4× (5.15%)
FY2018 3.6× (38.23%)
FY2017 5.8× 5.47%

Quarterly newest first

Period EV/Sales Change
Sep 2026 3.6× (5.83%)
Jun 2026 3.8× 7.78%
Mar 2026 3.5× (1.80%)
Dec 2025 3.6× 0.40%
43 more quarters

Against its own ten years

Low 2.9× High 5.9×
Ten-year median 4.0×
Current reading's percentile 12

EV/Sales against peers

Company EV/Sales
HCM HUTCHMED (China) Limited Sponsored ADR compare −0.1×
RGC Regencell Bioscience Holdings Limited compare n/m
PRGO Perrigo Company plc compare 1.2×
TRLV Trulieve Cannabis Corp. compare 2.0×
BCRX BioCryst Pharmaceuticals, Inc. compare 2.5×
PBH Prestige Consumer Healthcare Inc. 3.5×
XERS Xeris Biopharma Holdings, Inc. compare 6.7×
ALVO Alvotech compare 8.6×
AMLX Amylyx Pharmaceuticals, Inc. compare 32.5×
Drug Manufacturers Specialty & Generic industry median 2.9×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on PBH